Note: Single-source report; awaiting corroboration.
A National Institutes of Health (NIH)-funded study found that oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonists penetrate deep brain regions and suppress eating for pleasure by modulating a brain reward circuit in mice. This mechanism is distinct from previously understood effects on appetite control and involves the central amygdala, an area linked to desire.
The study examined small-molecule GLP-1 drugs such as orforglipron and danuglipron, which are FDA-approved or in development. These oral medications have the advantage of easier administration and lower production costs compared to injectable peptide GLP-1s like semaglutide. Researchers used gene editing to create mice with humanlike GLP-1 receptors and administered the drugs to observe changes in brain activity.
Results showed that beyond influencing known appetite-regulating regions, the drugs activated the central amygdala, leading to reduced dopamine release in key reward circuit hubs during hedonic feeding. This suggests oral small-molecule GLP-1 drugs may suppress pleasure-driven eating by engaging this reward pathway.
The findings raise questions about whether these next-generation GLP-1 drugs could also reduce cravings in other disorders involving reward processing, such as substance use disorder. Researchers plan to explore these effects in future studies.
Lorenzo Leggio, M.D., Ph.D., clinical director at NIH’s National Institute on Drug Abuse, emphasized the significance of understanding these neural mechanisms as more patients use these medications.